• Economy
  • Investing
  • Editor’s Pick
  • Stock
Keep Over Tradings
Stock

Nvidia stock plunges after Intel’s 18A move: what does it mean for AI chips?

by December 25, 2025
by December 25, 2025

Nvidia stock (NASDAQ: NVDA) tumbled nearly 1% on Wednesday after reports surfaced that the AI chipmaker has paused testing of Intel’s ambitious 18A manufacturing process.

The move marks a significant setback for Intel’s foundry revival strategy and reinforces questions about whether the chip giant can compete with Taiwan Semiconductor Manufacturing Company (TSMC).

Both Nvidia and Broadcom had been evaluating Intel’s 18A node over recent months, but the tests have stalled as performance and yield targets fell short of expectations.​

What the 18A pause means for Nvidia’s supply chain

Intel’s 18A process promised significant improvements over its previous generation: 30% higher transistor density, 25% faster performance at the same voltage, and up to 36% lower power consumption for equivalent throughput.

These specs matter because every watt saved translates to lower data center cooling bills, and every percentage point of density improvement means more AI compute per chip die.

Broadcom and Nvidia spent months running qualification tests, essentially manufacturing small batches of experimental chips to see how the new process would perform in the real world.​

The pause signals that those prototype runs didn’t deliver the goods.

When chip designers pull back from testing, it rarely means outright rejection.

Instead, it reflects either yield problems, performance shortfalls, or architectural mismatches that require more development time.

Broadcom had already flagged concerns, reportedly telling Intel engineers that 18A was “not currently viable for high-volume production” back in September.

Nvidia’s pause suggests similar issues remain unresolved.

For Nvidia, this is especially notable because the company operates on razor-thin timelines; new AI accelerators must launch on schedule or risk losing market share to competitors.

Sticking with proven TSMC capacity is the safer play.​

Intel emphasized that 18A remains “on track,” but the reality is blunt: a pause from Nvidia, the world’s most influential chip customer, reads as a vote of no confidence.

Competing against a foundry that already has 72% market share and a 41% revenue surge in Q3 2025 requires flawless execution.

Intel has already pushed back the 18A timeline twice, first to 2026, then to mid-2026 due to IP qualification delays, and customer hesitation only compounds the delays.​

Nvidia stock: Does this reshape the AI foundry map?

This development actually reinforces TSMC’s near-total dominance of advanced chip manufacturing.

The Taiwanese foundry controls nearly three-quarters of the market and is shipping the 3nm process at scale while maintaining 90% yields.

Samsung, Intel’s closest competitor, remains stuck with yield challenges of its own, even as it pushes its 2nm GAA (Gate-All-Around) technology.

For Nvidia and Broadcom, the path of least resistance is clear: keep working with TSMC.​

The Nvidia partnership announced in September 2025, which included a $5 billion investment by Nvidia, was supposed to be that breakthrough moment.

But the deal carefully avoided any manufacturing commitments. Nvidia CEO Jensen Huang explicitly stated the company would continue relying on TSMC. The 18A pause confirms that reality.​

For markets, uncertainty carries a heavier tax than bad news.

Intel shares fell 2-3% early Wednesday on the report. Nvidia, too, witnessed some correction, a sign that traders have already priced in the company’s dependence on TSMC.

Analysts like Angelo Zino from CFRA have warned that Intel’s foundry business will “continue to bleed cash at least through 2027,” while Samsung and TSMC will capture the lion’s share of AI chip production capacity.​

The post Nvidia stock plunges after Intel’s 18A move: what does it mean for AI chips? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Commodity wrap: gold, silver prices ease on Christmas Eve; oil heads for steepest drop since 2020
next post
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Related Posts

GLP-1 weight-loss pills set to reshape US food...

December 25, 2025

Why US sanctioned former EU official, 4 others;...

December 25, 2025

US stocks hold steady on Christmas Eve as...

December 25, 2025

Agios Pharma jumps 15% as FDA expands use...

December 25, 2025

Commodity wrap: gold, silver prices ease on Christmas...

December 25, 2025

Wall Street close: S&P 500 ends at record...

December 25, 2025

Europe bulletin: FTSE slips, US-EU clash escalates, Secure...

December 25, 2025

Evening digest: Bitcoin drifts as S&P 500 hits...

December 25, 2025

Tesla finds stability in energy as Rivian tests...

December 25, 2025

CoreWeave stock soars on DOE news and analyst...

December 21, 2025

Recent Posts

  • Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift
  • GLP-1 weight-loss pills set to reshape US food demand in 2026
  • US stocks hold steady on Christmas Eve as investors watch Santa Claus rally
  • Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat
  • Nvidia stock plunges after Intel’s 18A move: what does it mean for AI chips?

    Master Your Money – Sign Up for Our Financial Education Newsletter!


    Ready to take your financial knowledge to the next level? Our newsletter delivers easy-to-understand guides, expert advice, and actionable tips straight to your inbox. Whether you're saving for a dream vacation or planning for retirement, we’ve got you covered. Sign up today and start your journey to financial freedom!

    Recent Posts

    • Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

      December 25, 2025
    • GLP-1 weight-loss pills set to reshape US food demand in 2026

      December 25, 2025
    • US stocks hold steady on Christmas Eve as investors watch Santa Claus rally

      December 25, 2025
    • Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

      December 25, 2025
    • Nvidia stock plunges after Intel’s 18A move: what does it mean for AI chips?

      December 25, 2025
    • Commodity wrap: gold, silver prices ease on Christmas Eve; oil heads for steepest drop since 2020

      December 25, 2025

    Editors’ Picks

    • 1

      Europe bulletin: UK borrowing eases, France budget deadlock deepens, geopolitical risks rise

      December 21, 2025
    • 2

      Brazil’s Ibovespa gains on Blue-Chip strength amid budget vote, global cues

      December 21, 2025
    • 3

      Smartphones and PCs are about to get expensive next year; here’s why

      December 21, 2025
    • 4

      Trump secures deals with nine pharma firms to lower US drug prices, avert tariffs

      December 21, 2025
    • 5

      Evening digest: Bitcoin ETF inflows surge, BOJ hikes rates, FTC Clears Nvidia-Intel deal

      December 21, 2025
    • 6

      Business Conditions Monthly: October Showed Slowing Inflation, Waning Momentum

      December 21, 2025
    • 7

      China is ‘leaps and bounds ahead’ in robotics, experts says

      December 21, 2025

    Categories

    • Economy (7)
    • Editor’s Pick (3)
    • Investing (47)
    • Stock (20)
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: keepovertrading.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 keepovertrading.com | All Rights Reserved

    Keep Over Tradings
    • Economy
    • Investing
    • Editor’s Pick
    • Stock
    Keep Over Tradings
    • Economy
    • Investing
    • Editor’s Pick
    • Stock
    Disclaimer: keepovertrading.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 keepovertrading.com | All Rights Reserved

    Read alsox

    Agios Pharma jumps 15% as FDA expands...

    December 25, 2025

    US midday market brief: stocks rise as...

    December 21, 2025

    GLP-1 weight-loss pills set to reshape US...

    December 25, 2025